Among participants who met the core RESTORE-ALS Trial criteria (e.g., baseline serum NfL > 33 pg/mL, TRICALS risk score range between –6.5 and –2.5, baseline slow vital capacity > 60%, and symptom ...

A new study compares three types of blood biomarkers: neurofilament light chain proteins, glial acidic proteins and phosphorylated tau 181.

Ocrelizumab significantly reduced the number and volume of cortical lesions associated with multiple sclerosis at 120 weeks, ...

Motor neuron diseases are a group of fatal progressive disorders that rob the body and brain of the ability to function.

Fully human intranasal foralumab shows promise in treating Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS.

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder that is marked by fasciculation, spasticity and progressive weakness of muscles, and results in difficulty speaking ...

Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS)On-track to enable ...

Tetramethylpyrazine nitrone was safe for people with amyotrophic lateral sclerosis (ALS), but neither a high nor low daily ...

A blood test can help doctors detect ALS, or amyotrophic lateral sclerosis, and predict how the degenerative disease ...

For the study, researchers compared blood samples from 139 patients with ALS against 70 from patients with other similar ...

ALS, or amyotrophic lateral sclerosis, can sometimes be difficult to diagnose or to predict how quickly the disease is likely to progress. A new study helps determine which blood tests are best at ...

Systemic sclerosis (SSc) primary heart involvement (SSc‐pHI) is one of the leading causes of mortality in SSc. We aimed to evaluate risk factors for SSc‐pHI and its progression and the outcomes in the ...